Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1426 - 1426 of 1426

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1576 - 1600 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Status	Project Number
Rydapt for Acute Myeloid Leukemia – Details	pcodr_profund_midostaurin_rydapt_aml.pdf pcodr_midostaurin_rydapt_all_fn_rec.pdf pcodr_midostaurin_rydapt_all_fn_cgr.pdf pcodr_midostaurin_rydapt_all_fn_egr.pdf pcodr_midostaurin_rydapt_all_in_rec.pdf pcodr_midostaurin_rydapt_all_pagfdk.pdf pcodr_midostaurin_rydapt_all_fdk_novartis.pdf pcodr_midostaurin_rydapt_all_clnfdk.pdf pcodr_midostaurin_rydapt_all_coi_pt.pdf pcodr_midostaurin_rydapt_all_coi_cln.pdf	Jan 11, 2018	Reimbursement Review	Complete	PC0108-000
Opdivo in combo with Yervoy for Metastatic Melanoma – Details	pcodr_profund_opdivo_yervoy_metmela.pdf pcodr_opdivo_yervoy_metmela_fn_rec.pdf pcodr_opdivo_yervoy_metmela_fn_cgr.pdf pcodr_opdivo_yervoy_metmela_fn_egr.pdf pcodr_opdivo_yervoy_metmela_in_rec.pdf pcodr_opdivo_yervoy_metmela_pagfdk.pdf pcodr_opdivo_yervoy_metmela_fdk_bms.pdf pcodr_opdivo_yervoy_metmela_ptfdk_mnc.pdf pcodr_opdivo_yervoy_metmela_ptfdk_sys.pdf pcodr_opdivo_yervoy_metmela_clfdk.pdf pcodr_opdivo_yervoy_metmela_coi_pt.pdf pcodr_opdivo_yervoy_metmela_coi_cl.pdf	Dec 18, 2017	Reimbursement Review	Complete	PC0098-000
abobotulinumtoxinA	dysport-therapeutic-product-monograph.pdf SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf SR0517_Dysport_Therapeutic_CL_Report.pdf SR0517_Dysport_Therapeutic_PE_Report.pdf SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf	Nov 23, 2017	Reimbursement Review	Complete	SR0517-000
Tafinlar & Mekinist in combo for Non-Small Cell Lung Cancer – Details	pcodr_provfund_tafinlar_mekinist_nsclc.pdf pcodr_tafinlar_mekinist_nsclc_fn_rec.pdf pcodr_tafinlar_mekinist_nsclc_fn_cgr.pdf pcodr_tafinlar_mekinist_nsclc_fn_egr.pdf pcodr_tafinlar_mekinist_nsclc_in_rec.pdf pcodr_tafinlar_mekinist_nsclc_pagfdk.pdf pcodr_tafinlar_mekinist_nsclc_fdk_novartis.pdf pcodr_tafinlar_mekinist_nsclc_ptfdk.pdf pcodr_tafinlar_mekinist_nsclc_clfdk.pdf pcodr_tafinlar_mekinist_nsclc_coi-cl.pdf pcodr_tafinlar_mekinist_nsclc_coi-pt.pdf	Nov 17, 2017	Reimbursement Review	Complete	PC0106-000
Darzalex for Multiple Myeloma (second-line or beyond) – Details	pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf	Oct 24, 2017	Reimbursement Review	Complete	PC0104-000
Lynparza for Ovarian Cancer (Resubmission) – Details	pcodr_profund_olaparib_lynparza_resub.pdf pcodr_olaparib_lynparza_resub_fn_rec.pdf pcodr_olaparib_lynparza_resub_fn_cgr.pdf pcodr_olaparib_lynparza_resub_fn_egr.pdf pcodr_olaparib_lynparza_resub_in_rec.pdf pcodr_olaparib_lynparza_resub_pagfdk.pdf pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf pcodr_olaparib_lynparza_resub_ptfdk.pdf pcodr_olaparib_lynparza_resub_clinfdk.pdf pcodr_olaparib_lynparza_resub_coi_pt.pdf pcodr_olaparib_lynparza_resub_coi_clin.pdf	Oct 5, 2017	Reimbursement Review	Complete	PC0103-000
Insulin lispro		Sep 27, 2017	Reimbursement Review	Cancelled	SE0543-000
Blincyto for Acute Lymphoblastic Leukemia (Resubmission) – Details	pcodr_profund_blinatumomab_blincyto_all_resub.pdf pcodr_blinatumomab_blincyto_all_resub_fn_rec.pdf pcodr_blinatumomab_blincyto_all_resub_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_resub_fn_egr.pdf pcodr_blinatumomab_blincyto_all_resub_in_rec.pdf pcodr_blinatumomab_blincyto_all_resub_pagfdk.pdf pcodr_blinatumomab_blincyto_all_resub_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_resub_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_resub_coi_clinician.pdf	Sep 18, 2017	Reimbursement Review	Complete	PC0097-000
Rituxan for Acute Lymphoblastic Leukemia – Details	pcodr_profund_rituximab_rituxan_all.pdf pcodr_rituximab_rituxan_all_fn_rec.pdf pcodr_rituximab_rituxan_all_fn_cgr.pdf pcodr_rituximab_rituxan_all_fn_egr.pdf pcodr_rituximab_rituxan_all_in_rec.pdf pcodr_rituximab_rituxan_all_pagfdk.pdf pcodr_rituximab_rituxan_all_fdk_hlroche.pdf pcodr_rituximab_rituxan_all_coi_clinician.pdf	Sep 18, 2017	Reimbursement Review	Complete	PC0102-000
Opdivo for Squamous Cell Carcinoma of the Head and Neck (SCCHN) – Details	pcodr_profund_nivolumab_opdivo_scchn.pdf pcodr_nivolumab_opdivo_scchn_fn_rec.pdf pcodr_nivolumab_opdivo_scchn_fn_cgr.pdf pcodr_nivolumab_opdivo_scchn_fn_egr.pdf pcodr_nivolumab_opdivo_scchn_in_rec.pdf pcodr_nivolumab_opdivo_scchn_pagfdk.pdf pcodr_nivolumab_opdivo_scchn_fdk_bms.pdf pcodr_nivolumab_opdivo_scchn_coi_ptgrp.pdf	Sep 18, 2017	Reimbursement Review	Complete	PC0095-000
Keytruda for Advanced Non-Small Cell Lung Carcinoma (First Line) – Details	PembrolizumabKeytruda_AdvancedNSCLCfirstline10101_ProvFunding.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_ptgrp.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_clinician.pdf	Sep 8, 2017	Reimbursement Review	Complete	PC0101-000
Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia (pediatric) – Details	pcodr_profund_blinatumomab_blincyto_all_pediatric.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_egr.pdf pcodr_blinatumomab_blincyto_all_pediatric_in_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_pagfdk.pdf pcodr_blinatumomab_blincyto_all_pediatric_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_clinician.pdf	Sep 8, 2017	Reimbursement Review	Complete	PC0099 -000
Ninlaro for Multiple Myeloma – Details	pcodr_provfund_ixazomib_ninlaro_mm.pdf pcodr_ixazomib_ninlaro_mm_fn_rec.pdf pcodr_ixazomib_ninlaro_mm_fn_cgr.pdf pcodr_ixazomib_ninlaro_mm_fn_egr.pdf pcodr_ixazomib_ninlaro_mm_in_rec.pdf pcodr_ixazomib_ninlaro_mm_pagfdk.pdf pcodr_ixazomib_ninlaro_mm_fdk_takeda.pdf pcodr_ixazomib_ninlaro_mm_ptfdk.pdf pcodr_ixazomib_ninlaro_mm_clnfdk.pdf pcodr_ixazomib_ninlaro_mm_coi_mmc.pdf pcodr_ixazomib_ninlaro_mm_coi_cln.pdf	Jul 17, 2017	Reimbursement Review	Complete	PC0088-000
RFA: Inlyta for Metastatic Renal Cell Carcinoma	pcodr_rfa_axitinib_inlyta_mrcc_rfa_rec.pdf pcodr_rfa_axitinib_inlyta_mrcc_rfa_cgr.pdf pcodr_rfa_axitinib_inlyta_mrcc_fdk_pfizer.pdf pcodr_rfa_axitinib_inlyta_mrcc_fdk_kcc.pdf	Jun 30, 2017	Reimbursement Review	Complete	PA0001-000
Gazyva for Follicular Lymphoma – Details	pcodr_profund_obinutuzumab_gazyva_fl.pdf pcodr_obinutuzumab_gazyva_fl_fn_rec.pdf media:document:b525feb5-dfab-4fab-9329-39565d03e75a media:document:e96c2560-fd09-4813-ac09-a3cef1e32514 pcodr_obinutuzumab_gazyva_fl_fn_cgr.pdf pcodr_obinutuzumab_gazyva_fl_fn_egr.pdf pcodr_obinutuzumab_gazyva_fl_in_rec.pdf pcodr_obinutuzumab_gazyva_fl_pagfdk.pdf pcodr_obinutuzumab_gazyva_fl_fdk_roche.pdf pcodr_obinutuzumab_gazyva_fl_ptfdk.pdf pcodr_obinutuzumab_gazyva_fl_coi_pt.pdf	Jun 19, 2017	Reimbursement Review	Complete	PC0091-000
Evolocumab	cdr_SR0515_Repatha.pdf SR0515_Repatha_Resubmission_complete_Nov_24_17.pdf SR0515_Repatha_Resubmission_CL_Report.pdf SR0515_Repatha_Resubmission_PE_Report.pdf SR0515_Repatha_PI_Submissions.pdf	Jun 8, 2017	Reimbursement Review	Complete	SR0515-000
New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report		May 23, 2017	Health Technology Review		TR0012-000
Tagrisso for Non-Small Cell Lung Cancer – Details	pcodr_provfund_10076_osimertinib_tagrisso_nsclc.pdf pcodr_osimertinib_tagrisso_nsclc_fn_rec.pdf pcodr_osimertinib_tagrisso_nsclc_fn_cgr.pdf pcodr_osimertinib_tagrisso_nsclc_fn_egr.pdf pcodr_osimertinib_tagrisso_nsclc_in_rec.pdf pcodr_osimertinib_tagrisso_nsclc_pagfdk.pdf pcodr_osimertinib_tagrisso_nsclc_fdk_azc.pdf pcodr_osimertinib_tagrisso_nsclc_ptfdk.pdf pcodr_osimertinib_tagrisso_nsclc_clnfdk.pdf pcodr_osimertinib_tagrisso_nsclc_coi_pt.pdf pcodr_osimertinib_tagrisso_nsclc_coi_cln.pdf	May 19, 2017	Reimbursement Review	Complete	PC0076-000
Alecensaro for Non-Small Cell Lung Cancer (with CNS metastases) – Details	pcodr_provfund_alectinib_alecensaro_nsclc.pdf pcodr_alectinib_alecensaro_nsclc_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_fn_cgr.pdf pcodr_alectinib_alecensaro_nsclc_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_ptfdk.pdf pcodr_alectinib_alecensaro_nsclc_clnfdk.pdf pcodr_alectinib_alecensaro_nsclc_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_coi_cln.pdf	May 19, 2017	Reimbursement Review	Complete	PC0092-000
Mifepristone and misoprostol	cdr_SR0502_Mifegymiso.pdf SR0502_complete_Mifegymiso-Apr-20-17-e.pdf SR0502_Mifegymiso_CL_Report.pdf SR0502_Mifegymiso_PE_Report.pdf	Apr 20, 2017	Reimbursement Review	Complete	SR0502-000
Caprelsa for Medullary Thyroid Cancer – Details	pcodr_provfund_vandetanib_caprelsa_mtc.pdf pcodr_vandetanib_caprelsa_mtc_fn_rec.pdf pcodr_vandetanib_caprelsa_mtc_fn_cgr.pdf pcodr_vandetanib_caprelsa_mtc_fn_egr.pdf pcodr_vandetanib_caprelsa_mtc_in_rec.pdf pcodr_vandetanib_caprelsa_mtc_pagfdk.pdf pcodr_vandetanib_caprelsa_mtc_fdk_sanofig.pdf pcodr_vandetanib_caprelsa_mtc_ptfdk_tcc.pdf pcodr_vandetanib_caprelsa_mtc_coi_tcc.pdf pcodr_vandetanib_caprelsa_mtc_coi_cln.pdf	Apr 17, 2017	Reimbursement Review	Complete	PC0090-000
Kyprolis for Multiple Myeloma (relapsed) – Details	pcodr_profund_carfilzomib_kyprolis_mm_rel.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_rec.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_cgr.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf pcodr_carfilzomib_kyprolis_mm_rel_in_rec.pdf pcodr_carfilzomib_kyprolis_mm_rel_fdk_amgen.pdf pcodr_carfilzomib_kyprolis_mm_rel_pagfdk.pdf pcodr_carfilzomib_kyprolis_mm_rel_ptfdk_mmc.pdf pcodr_carfilzomib_kyprolis_mm_rel_fdk_cln.pdf pcodr_carfilzomib_kyprolis_mm_rel_coi_mmc.pdf pcodr_carfilzomib_kyprolis_mm_rel_coi_cln.pdf	Apr 17, 2017	Reimbursement Review	Complete	PC0084-000
Avastin for Malignant Pleural Mesothelioma – Details		Apr 11, 2017	Reimbursement Review	Withdrawn	PC0100-000
Zykadia for Non-Small Cell Lung Cancer (Resubmission) – Details	pcodr_provfund_ceritinib_zykadia_nsclc_resub.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_rec.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_cgr.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_egr.pdf pcodr_ceritinib_zykadia_nsclc_resub_in_rec.pdf pcodr_ceritinib_zykadia_nsclc_resub_pagfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_fdk_novartis.pdf pcodr_ceritinib_zykadia_nsclc_resub_ptfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_clinfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_coi_lcc.pdf pcodr_ceritinib_zykadia_nsclc_resub_coi_clin.pdf	Apr 5, 2017	Reimbursement Review	Complete	PC0094-000
Buprenorphine Implant for the Treatment of Opioid Use Disorder		Mar 21, 2017	Horizon Scan	Completed	EH0044-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81